Two Doses of LY2189265 or Exenatide on Glycemic Control in Type 2 Diabetes (AWARD-1)
Diabetes Mellitus, Type 2
Enrolment: 978 · Results not recorded
Loading the evidence…
Hormone · GLP-1 receptor agonist (ChEMBL mec_id 60, AGONIST, direct interaction, FDA label ref). Synthetic exendin-4, a 39-amino-acid incretin mimetic originally isolated from Heloderma suspectum venom. ATC A10BJ01. Black box warning (thyroid C-cell tumours, extended-release form).
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Diabetes Mellitus, Type 2
Enrolment: 978 · Results not recorded
Type 2 Diabetes Mellitus
Enrolment: 467 · Results not recorded
Hyperinsulinemic Hypoglycemia
Enrolment: 11 · Results not recorded
Obesity
Enrolment: 10 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Full skin thickness scald injury covering 50 per cent total body surface area
Exendin-4 reduced islet and beta-cell histopathological damage and apoptosis index, increased insulin and reduced glucagon in islets and plasma, and improved intraperitoneal glucose tolerance and fasting blood glucose (all P < 0.05).
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
Model: Transient middle cerebral artery occlusion for 60 min with an intraluminal thread, with hyperglycaemia induced by intraperitoneal dextrose 15 min before occlusion
Hyperglycaemia increased infarct volume (36.3 +/- 1.20 versus 26.9 +/- 1.28), oedema and haemorrhagic transformation. Exendin-4, but not insulin, reduced matrix metalloproteinase-9 activation, tumour necrosis factor alpha and oxidative stress markers, and reduced infarct volume at 24 h (23.6 +/- 0.…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.